Detecting Tumor Specific Amplitude-modulated Frequencies of Cancer Patients
NCT ID: NCT03037840
Last Updated: 2018-10-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2018-12-31
2020-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Therapeutic Amplitude-modulated Electromagnetic Fields in Advanced Tumors
NCT00440570
Neurofeedback in Decreasing Acute Radiotherapy-Induced Pain in Patients With Head and Neck Cancer
NCT02543320
Combined Radiotherapy and Radiofrequency Ablation for Hepatocellular Carcinoma
NCT04202523
Low Levels of Electromagnetic Fields to Treat Advanced Cancer
NCT00805337
TOMO Versus IMRT in Nasopharyngeal Carcinoma Patients
NCT03588403
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
cancer patients
Low intensity amplitude-modulated RF EMFs
Low intensity amplitude-modulated RF EMFs
Low intensity amplitude-modulated radiofrequency electromagnetic fields,the carrier frequency is 27.12MHz with a power of about 100mW
healthy participators
Low intensity amplitude-modulated RF EMFs
Low intensity amplitude-modulated RF EMFs
Low intensity amplitude-modulated radiofrequency electromagnetic fields,the carrier frequency is 27.12MHz with a power of about 100mW
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Low intensity amplitude-modulated RF EMFs
Low intensity amplitude-modulated radiofrequency electromagnetic fields,the carrier frequency is 27.12MHz with a power of about 100mW
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nanfang Hospital, Southern Medical University
OTHER
Guangdong 999 Brain Hospital
OTHER
The 157th Hospital of PLA,China
UNKNOWN
Southern Medical University, China
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sherman Xuegang Xin
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xin Sherman Xuegang, professor
Role: PRINCIPAL_INVESTIGATOR
School of Biomedical Engineering,Southern Medical University
Cai Linbo, master
Role: STUDY_DIRECTOR
Guangdong 999 Brain Hospital
Zhu Xiaoxia, PhD
Role: STUDY_DIRECTOR
Nanfang Hospital, Southern Medical University
Liu Xiantang, bachelor
Role: STUDY_DIRECTOR
The 157th Hospital of PLA
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Barbault A, Costa FP, Bottger B, Munden RF, Bomholt F, Kuster N, Pasche B. Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach. J Exp Clin Cancer Res. 2009 Apr 14;28(1):51. doi: 10.1186/1756-9966-28-51.
Costa FP, de Oliveira AC, Meirelles R, Machado MC, Zanesco T, Surjan R, Chammas MC, de Souza Rocha M, Morgan D, Cantor A, Zimmerman J, Brezovich I, Kuster N, Barbault A, Pasche B. Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields. Br J Cancer. 2011 Aug 23;105(5):640-8. doi: 10.1038/bjc.2011.292. Epub 2011 Aug 9.
Zimmerman JW, Pennison MJ, Brezovich I, Yi N, Yang CT, Ramaker R, Absher D, Myers RM, Kuster N, Costa FP, Barbault A, Pasche B. Cancer cell proliferation is inhibited by specific modulation frequencies. Br J Cancer. 2012 Jan 17;106(2):307-13. doi: 10.1038/bjc.2011.523. Epub 2011 Dec 1.
Zimmerman JW, Jimenez H, Pennison MJ, Brezovich I, Morgan D, Mudry A, Costa FP, Barbault A, Pasche B. Targeted treatment of cancer with radiofrequency electromagnetic fields amplitude-modulated at tumor-specific frequencies. Chin J Cancer. 2013 Nov;32(11):573-81. doi: 10.5732/cjc.013.10177.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SXXin-AM-RF-EMF-in vivo
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.